

Topical Collection

Hereditary Gastrointestinal Cancer Syndromes: Molecular Basis of Onset and Progression, Molecular Diagnosis, and Precision Therapy

Message from the Collection Editor

This Topical Collection, entitled “Hereditary Gastrointestinal Cancer Syndromes: Molecular Basis of Onset and Progression, Molecular Diagnosis, and Precision Therapy” will mainly focus on the principal roles that hereditary gastrointestinal cancer predisposing syndromes play on colorectal cancer incidence, the molecular basis of their onset and progression, the discovery of innovative therapies for disease management and care, and the standardization of novel approaches for early diagnosis and cancer prevention. Colorectal cancer (CRC) is the third most frequent cancer worldwide. About 75% of all CRCs are sporadic cancers and arise following somatic mutations, while about 10% of all CRCs are hereditary cancers, among which are hereditary nonpolyposis colorectal cancer, adenomatous and hamartomatous polyposis syndromes, and gastric adenocarcinoma and proximal polyposis of the stomach. We thus consider this subject to be of particular interest because new knowledge can help toward early asymptomatic diagnosis, cancer prevention, and standardization of new therapeutic approaches.

Collection Editor

Prof. Dr. Marina De Rosa

1. Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy
 2. Ceinge Biotechnologie Avanzate, 80131 Naples, Italy
-



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/111747

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).